drugset
drugset / Trial / NCT02826044

The Pharmacokinetics Study of Single and Multiple Dose of SP2086 in Healthy Volunteers

NCT02826044 ↗

Phase 1 Unknown 30 enrolled Jiangsu HengRui Medicine Co., Ltd.
Non-randomizedFactorialOpen-labelTreatment

Summary

SP2086 is a novel inhibitor of Dipeptide base peptidase 4, allows an insulin-independent approach to improve type 2 diabetes hyperglycemia. In this single-dose and multiple-dose study the investigators evaluated the safety, tolerability and Pharmacokinetics profiles of SP2086 in healthy volunteers.

Timeline

Start
2016-07
Primary completion
2016-09
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Retagliptin Small molecule 50 mg —
Subject Retagliptin Small molecule 100 mg —
Subject Retagliptin Small molecule 200 mg —

Indications

type 2 diabetes mellitus